Business Wire

NJ-DRIVEWEALTH

13.7.2022 15:02:09 CEST | Business Wire | Press release

Share
DriveWealth Global Investor Study: Millennials Move Beyond Meme Stocks, Demand More Choices as Trading Remained High Despite Market Lows

DriveWealth, LLC , a global fintech investment rail and pioneer in fractional investing, today released its new DriveTrends study, “The Year of The Millennial Trader: Trading Remained Trendy Despite Market Uncertainty ,” a closer look at how the first prolonged bear market many investors have faced impacted trading behaviors of millions across APAC, EMEA, LATAM, and the U.S. during the first half of 2022. The study analyzes data of more than 12 million investors worldwide who trade shares of U.S. equities through DriveWealth’s network of 100+ global partners, including Block Inc.’s Cash App, Revolut, and Navy Federal Financial Group.

Even amid market lows, data shows trading remained popular among Millennials, a demographic that continues to demand more access to traditional and alternative investment products and tools. The report showcases how Millennials’ increasing preference for innovations like fractional equity trades and diversified portfolios have shaped a new market for digital wallet app users , which is anticipated to exceed 4.4 billion by 2025, according to Juniper Research .

“The ability for providers to offer fractionalized trading has provided a whole new segment of consumers with the opportunity to access wealth creating markets using the smartphones they already own,” said Harry Temkin , Chief Information Officer at DriveWealth. “Millennials are motivating fintechs and neobanks to innovate their product suite to improve access to U.S. equities and financial literacy tools in underserved markets. Our recent partnerships with companies like Toss Securities , Goalsetter , and Sproutfi are testaments to the amount of power Millennials have to shape the financial ecosystem at large – all they need is an investment button that’s now accessible in the palm of their hand.”

Based on data from the first half of 20221 , key takeaways from the report include:

  • Millennials represented the largest proportion of new investment account openings worldwide at 46%. While data showed that almost half of Gen-Z investors opened their first account during the March 2020 to August 2021 period (representing a large and growing market share of investors), Gen-Z scaled back while Millennials took the lead this year. This could signal a potential influx of cash into investment platforms that meet their investing needs, as U.S. Millennial wealth has more than doubled from the fourth quarter of 2019 to the end of 2021.
  • While ‘meme stocks’ and Reddit comments continued to inspire news headlines, the report shows global investors (especially younger ones) gravitated toward more tried-and-true names to create their portfolios. AAPL, TSLA, and AMZN continue to retain their position as the top three symbols traded worldwide.
  • Millennials represented both the highest average trades per account (19) worldwide and the largest proportion of trades in each region. This generation drove:
    • 94% of trades in APAC
    • 69% of trades in EMEA
    • 53% of trades in LATAM
    • 53% of trades in the U.S.
  • Across the U.S., LATAM, and EMEA, approximately 96% of all activity was driven by fractionalized trades through DriveWealth’s platform. This is a measurable increase from the second half of 2020, where fractional trades drove 92% of global activity.
  • The top two traded symbols among Millennials in APAC were TQQQ and SQQQ, triple-leveraged ETFs that track a Nasdaq 100 index ETF, QQQ. Known as a high-risk sector, this suggests Millennials in this region may be motivated by riskier investments with the potential for high returns.

“As we dive deeper into the Decade of the Digital Investor , we’re seeing a paradigm shift in investing,” said Gayathri Rajan , Chief Product Officer at DriveWealth. “Despite market uncertainty, people – especially younger investors – are still investing in the brands they love using digital tools that are making markets accessible and affordable for them. As a pioneer of fractional trading, we’re excited to continue working with our partners to develop even more ways for investors worldwide to access the markets through our API-based platform.”

To read the full results of “The Year of The Millennial Trader: Trading Remained Trendy Despite Market Uncertainty,” click here . For more information on DriveWealth’s full suite of services, see here .

About DriveWealth

DriveWealth , a global fintech investment rail and pioneer of fractional equities trading, is a visionary technology company that empowers more than 100 partners around the world to engage their customers by placing the markets in the palm of their hands. We believe the future is fractional, transactional and mobile. Every mobile device should be a gateway to accessing investing and savings products, services, advice, and assistance for global citizens of all ages, wealth stages, and levels of financial expertise. DriveWealth’s consultative support and cloud-based, modern technology platform allow partners to seamlessly offer branded investing experiences to drive customer acquisition, loyalty, retention, and revenue growth. For more information, please visit drivewealth.com or connect with us on Twitter @DriveWealth or on LinkedIn .

1 DriveWealth proprietary data. All data has been rounded and reflects approximate figures.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye